163 related articles for article (PubMed ID: 37092519)
1. Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Liu A; Vicenzi P; Sharma I; Orr K; Teller C; Koentz M; Trinkman H; Vallance K; Ray A
Hematol Rep; 2023 Apr; 15(2):244-255. PubMed ID: 37092519
[TBL] [Abstract][Full Text] [Related]
2. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
4. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
5. Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer.
Behel V; Noronha V; Choughule A; Shetty O; Chandrani P; Kapoor A; Bondili SK; Bajpai J; Kumar R; Pai T; Bal M; Gurav M; Bapat P; Mittal N; Menon S; Patil V; Menon N; Dutt A; Prabhash K
JCO Glob Oncol; 2022 Jul; 8():e2200030. PubMed ID: 35802838
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
[TBL] [Abstract][Full Text] [Related]
8. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R
J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005
[TBL] [Abstract][Full Text] [Related]
9. Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine.
Ballatore Z; Bozzi F; Cardea S; Savino FD; Migliore A; Tarantino V; Chiodi N; Ambrosini E; Bianchi F; Goteri G; Filosa A; Barbisan F; Bartoli E; Papa R; Berardi R
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892804
[No Abstract] [Full Text] [Related]
10. Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.
Rieke DT; Lamping M; Schuh M; Le Tourneau C; Basté N; Burkard ME; Metzeler KH; Leyvraz S; Keilholz U
JCO Precis Oncol; 2018 Nov; 2():1-14. PubMed ID: 35135153
[TBL] [Abstract][Full Text] [Related]
11. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.
Koopman B; van der Wekken AJ; Ter Elst A; Hiltermann TJN; Vilacha JF; Groves MR; van den Berg A; Hiddinga BI; Hijmering-Kappelle LBM; Stigt JA; Timens W; Groen HJM; Schuuring E; van Kempen LC
JCO Precis Oncol; 2020 Nov; 4():393-410. PubMed ID: 35050740
[TBL] [Abstract][Full Text] [Related]
12. Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.
Sotelo-Rodríguez C; Vallejo-Ardila D; Ruiz-Patiño A; Chamorro DF; Rodríguez J; Moreno-Pérez DA; Carranza H; Otero J; Vargas C; Archila P; Rojas L; Zuluaga J; Rubio C; Ordóñez-Reyes C; Garcia-Robledo JE; Mejía S; Jaller E; Arrieta O; Cardona AF
JCO Glob Oncol; 2024 Jan; 10():e2300011. PubMed ID: 38237094
[TBL] [Abstract][Full Text] [Related]
13. Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital.
Trivedi H; Acharya D; Chamarthy U; Meunier J; Ali-Ahmad H; Hamdan M; Herman J; Srkalovic G
Acta Med Acad; 2019 Apr; 48(1):105-115. PubMed ID: 31264438
[TBL] [Abstract][Full Text] [Related]
14. Primary Results of Patients with Genitourinary Malignancies Presented at a Molecular Tumor Board.
Michaelis J; Himmelsbach R; Metzger P; Lassmann S; Börries M; Werner M; Miething C; Höfflin R; Illert AL; Duyster J; Becker H; Sigle A; Gratzke C; Grabbert M
Urol Int; 2024 Apr; ():1-9. PubMed ID: 38626735
[TBL] [Abstract][Full Text] [Related]
15. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
[TBL] [Abstract][Full Text] [Related]
16. Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial.
Miller RW; Hutchcraft ML; Weiss HL; Wu J; Wang C; Liu J; Jayswal R; Buchanan M; Anderson A; Allison DB; El Khouli RH; Patel RA; Villano JL; Arnold SM; Kolesar JM
JCO Precis Oncol; 2022 Aug; 6():e2100524. PubMed ID: 36103643
[TBL] [Abstract][Full Text] [Related]
17. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.
Naito Y; Sunami K; Kage H; Komine K; Amano T; Imai M; Koyama T; Ennishi D; Kanai M; Kenmotsu H; Maeda T; Morita S; Sakai D; Watanabe K; Shirota H; Kinoshita I; Yoshioka M; Mamesaya N; Ito M; Kohsaka S; Saigusa Y; Yamamoto K; Hirata M; Tsuchihara K; Yoshino T
JAMA Netw Open; 2022 Dec; 5(12):e2245081. PubMed ID: 36469316
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Rolfo C; Manca P; Salgado R; Van Dam P; Dendooven A; Ferri Gandia J; Rutten A; Lybaert W; Vermeij J; Gevaert T; Weyn C; Lefebure A; Metsu S; Van Laere S; Peeters M; Pauwels P; Machado Coelho A
ESMO Open; 2018; 3(5):e000398. PubMed ID: 30094075
[TBL] [Abstract][Full Text] [Related]
19. Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center.
Tögel L; Schubart C; Lettmaier S; Neufert C; Hoyer J; Wolff K; Moskalev EA; Stöhr R; Agaimy A; Reis A; Wullich B; Mackensen A; Pavel M; Beckmann MW; Hartmann A; Fietkau R; Meidenbauer N; Haller F; Spoerl S
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136436
[TBL] [Abstract][Full Text] [Related]
20. Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Bernhardt EB; Chamberlin MD; Gorlov IP; de Abreu FB; Bloch KJ; Peterson JD; Tsongalis GJ; Shirai K; Dragnev KH; Miller TW; Tafe LJ
Pract Lab Med; 2020 Aug; 21():e00174. PubMed ID: 32613070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
